Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis

Table 4 Multivariate analysis of prognostic factors for 170 patients with stage T3-4N1 NPC

Variables	OS		LRFS		DRFS		RFS
Variables	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Smoking history (yes vs. no)	2.612 (1.027–6.645)	0.044	–	–	–	–	1.840 (0.913–3.709)	0.088
T classification (T3 vs. T4)	2.846 (1.125–7.201)	0.027	–	–	–	–	1.590 (0.771–3.279)	0.209
PLNC (negative vs. positive)	2.414 (0.900–6.474)	0.080	–	–	4.522 (1.513–13.514)	0.007	2.583 (1.263–5.284)	0.009
Lymph node diameter (mm, maximum, < 15 vs. ≥15)	1.563 (0.597–4.094)	0.363	2.617 (1.084–6.318)	0.032	–	–	1.597 (0.783–3.256)	0.198

Abbreviations: NPC Nasopharyngeal carcinoma; HR Hazard ratio; CI Confidence interval; PLNC Pretreatment lymph node condition; EBV Epstein–Barr virus; OS Overall Survival; LRFS Locoregional recurrence-free survival; DRFS Distant recurrence-free survival; RFS Recurrence-free survival

ISSN: 1748-717X